跳至主要内容
临床试验/EUCTR2018-002579-16-SE
EUCTR2018-002579-16-SE进行中(未招募)1 期

Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus spp. related lung-disease. Part 1. Pharmacokinetic single center study.

Karolinska University Hospital, Stockholm CF center0 个研究点目标入组 12 人开始时间: 2018年7月16日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Confirmed diagnosis of cystic fibrosis
  • 2. = 18 and < 65 years of age
  • 3. Males and females
  • 4. Clinically stable disease (but different pulmonary status)
  • 5. Willing to participate in the study
  • 6. Willing to use contraceptives
  • 7. Signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 12
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Previous adverse event on posaconazole
  • 2. Ongoing treatment with posaconazol.
  • 3. Advanced liver disease
  • 4. Prolonged QTc-interval
  • 5. Pregnancy, breastfeeding
  • 6. Ongoing upper or lower respiratory infection requiring antibiotic treatment
  • 7. Ongoing treatment with compounds contraindicated according to FASS
  • 8. Ongoing or previous participation in a clinical pharmaceutical study within 28-days before screening.
  • 9. Investigator assesses that it is not an appropriate study for the patient

研究者

发起方
Karolinska University Hospital, Stockholm CF center

相似试验